Generic Name and Formulations:
Nortriptyline HCl 10mg, 25mg, 50mg, 75mg; caps.
Indications for PAMELOR:
Initially 25mg 3–4 times daily; max 150mg/day. Elderly and adolescents: 30–50mg/day in single or divided doses.
During or within 14 days of MAOIs. Concomitant linezolid or IV methylene blue. Acute post-MI.
Suicidality and antidepressant drugs.
Increased risk of suicidal thinking and behavior in children, adolescents and young adults; monitor for clinical worsening and unusual changes. Monitor for emergence of serotonin syndrome; discontinue if occurs. Mania/hypomania. Bipolar disorder. Psychosis. ECT. Cardiovascular disease. Angle-closure glaucoma. Urinary retention. Epilepsy. Hyperthyroidism. Diabetes. Liver disorders. Monitor plasma levels if dose >100mg/day. Elderly. Pregnancy. Nursing mothers.
See Contraindications. Increased risk of serotonin syndrome with other serotonergic drugs (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Potentiates alcohol, sympathomimetics. CNS stimulation with reserpine. Potentiated by CYP2D6 inhibitors; monitor plasma levels with quinidine, cimetidine, SSRIs, phenothiazines, type 1C antiarrhythmics (eg, propafenone, flecainide). Antagonized by barbiturates, carbamazepine. Paralytic ileus, hyperpyrexia with anticholinergics. Blocks guanethidine.
Drowsiness, anticholinergic effects, CNS overstimulation, arrhythmias, extrapyramidal symptoms, hypo- or hypertension, nausea, fatigue, rash, headache, changes in blood sugar, photosensitivity, edema, blood dyscrasias, jaundice.
Caps—30; Soln—contact supplier
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds